APP
PBYI icon

Avantax Planning Partners’s Puma Biotechnology PBYI Stock Holding History

Avantax Planning Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28
Closed -$2K – 1107
2018
Q1 		$2K Buy
+28
New +$2.1K ﹤0.01% 1615

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Avantax Planning Partners's PBYI Position: Q2 2018 in Review

Avantax Planning Partners sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 28 shares — an estimated $2K sold.

Avantax Planning Partners first reported a position in PBYI in Q1 2018 and held it in 1 quarter. The position peaked at $2K in Q1 2018. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

  • Avantax Planning Partners reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 28 Puma Biotechnology shares in Q2 2018, an estimated $2K.
  • Avantax Planning Partners first reported a position in Puma Biotechnology in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Puma Biotechnology position peaked at $2K in Q1 2018.
  • 174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.